Aurora Cannabis Partners with Strainprint to Empower Patients on their Cannabis Journey

Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) has announced the launch of a new tracking program to enhance the wellness journey of cannabis patients. Set to empower users alongside healthcare advice, the Strainprint® App allows users to record symptoms and consumption habits, helping them identify the most suitable cannabis strains and dosages. This initiative aligns with Aurora's commitment to improving patient lives through innovative solutions in the cannabis industry. The Strainprint App is available for free on both the Apple Store and Google Play Store. With a focus on quality and patient well-being, Aurora continues to advance in both medical and recreational cannabis sectors.

Positive

• Launch of Strainprint® App aimed at enhancing patient wellness.
• Patients can track symptoms and consumption habits for personalized care.
• Aurora's commitment to patient-first approach strengthens brand loyalty.

Negative

• None.

NASDAQ | TSX: ACB

EDMONTON, AB, April 26, 2023 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the launch of a new tracking program designed to support and empower cannabis patients on their wellness journey.

Alongside the advice of a healthcare professional, Aurora patients can use the award-winning Strainprint^® App journal to track their medical cannabis journey by logging their symptoms and consumption habits to better understand which strains, THC and CBD levels, ingestion methods and doses best work for them. Patients can also explore new products, learn more about strains and understand what has helped other patients through the App. All data entered and gathered by the Strainprint App is anonymous and aggregated.

"We take a patient-first approach to cannabis and are proud to provide our patients with programs that improve their lives and their medical cannabis journey," says Mike Jones, SVP of Medical at Aurora Cannabis. "By working with Strainprint, we can support our patients every step of the way, and further Aurora's promise to prioritize patient well-being and provide the highest quality products."

Patients can download the free Strainprint App on the Apple Store and Google Play Store.

About Strainprint

Based in Toronto, Canada, Strainprint^® Technologies is the leading data and analytics technology platform for medical and recreational cannabis use research. Since 2016, Strainprint^® has been providing decision-support research tools and data to cannabis patients, doctors, licensed producers, retailers, industry regulators, academic researchers and pharmaceutical/biotechnology companies across Canada, the U.S., Australia, Israel and New Zealand. With over 2.1 million real-time user-interactions logged against 9,500+ legal and lab-tested cannabis products on the Strainprint^® platform (over 100 million data points), Strainprint^® is also the most extensive real-world evidence (RWE) study on therapeutic cannabis use and its impact on over 300 therapeutic conditions and symptoms - Cannabis Big Data^®! Strainprint data is regularly published in peer-reviewed research journals, providing credibility, plus data-backed insight and formulation guidance for cannabis processors, pharmaceutical and therapeutics manufacturers and consumer packaged goods companies in the cosmetics, food and beverage industries. Strainprint Analytics can be seamlessly integrated with most electronic medical records, seed2sale, and point-of-sale software systems. The Strainprint journal App is free to patients and can be downloaded from both the IOS App Store and Google Play Store. www.strainprint.ca, facebook, twitter, linkedin.

For Inquiries: info@strainprint.ca

About Aurora

Aurora is opening the world to cannabis, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. as well as international brands, Pedanios, Bidiol and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on Twitter and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of the Strainprint app and the associated benefits for patients of the Company.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated September 20, 2022 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-partners-with-strainprint-to-empower-patients-on-their-cannabis-journey-301808361.html

SOURCE Aurora Cannabis Inc.

FAQ

What is the purpose of the Strainprint App launched by Aurora Cannabis?

The Strainprint App is designed to help cannabis patients track symptoms and consumption habits to enhance their wellness journey.

When was the Strainprint App launched by Aurora Cannabis?

The Strainprint App was announced on April 26, 2023.

What are the key features of the Strainprint App?

Key features include logging symptoms, tracking consumption habits, and exploring different cannabis products.

How can patients access the Strainprint App?

Patients can download the Strainprint App for free from the Apple Store and Google Play Store.

What is Aurora Cannabis's stock symbol?

Aurora Cannabis trades under the symbol ACB on NASDAQ and TSX.